As expected, compared to NAFLD/NASH patients, significantly lower serum glucose, adiponectin, insulin levels, and cytokeratin-18 fragments M30 and M65 levels were observed in healthy controls. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.